Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Détail de l'auteur
Auteur Amir LEVINE |
Documents disponibles écrits par cet auteur (1)
Faire une suggestion Affiner la recherche
Research Review: Pediatric anxiety disorders - what have we learnt in the last 10 years? / Jeffrey R. STRAWN in Journal of Child Psychology and Psychiatry, 62-2 (February 2021)
[article]
Titre : Research Review: Pediatric anxiety disorders - what have we learnt in the last 10 years? Type de document : Texte imprimé et/ou numérique Auteurs : Jeffrey R. STRAWN, Auteur ; Lu LU, Auteur ; Tara S. PERIS, Auteur ; Amir LEVINE, Auteur ; John T. WALKUP, Auteur Année de publication : 2021 Article en page(s) : p.114-139 Langues : Anglais (eng) Mots-clés : Generalized anxiety disorder Sri) fMRI pharmacogenomics selective serotonin reuptake inhibitor (SSRI separation anxiety disorder Index. décimale : PER Périodiques Résumé : BACKGROUND: Anxiety disorders first emerge during the critical developmental periods of childhood and adolescence. This review synthesizes recent findings on the prevalence, risk factors, and course of the anxiety disorders; and their neurobiology and treatment. METHODS: For this review, searches were conducted using PubMed, PsycINFO, and clinicaltrials.gov. Findings related to the epidemiology, neurobiology, risk factors, and treatment of pediatric anxiety disorders were then summarized. FINDINGS: Anxiety disorders are high prevalence, and early-onset conditions associated with multiple risk factors including early inhibited temperament, environment stress, and structural and functional abnormalities in the prefrontal-amygdala circuitry as well as the default mode and salience networks. The anxiety disorders are effectively treated with cognitive behavioral therapy (CBT), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine reuptake inhibitors (SNRIs). CONCLUSIONS: Anxiety disorders are high prevalence, early-onset conditions associated with a distinct neurobiological fingerprint, and are consistently responsive to treatment. Questions remain regarding who is at risk of developing anxiety disorders as well as the way in which neurobiology predicts treatment response. En ligne : http://dx.doi.org/10.1111/jcpp.13262 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=440
in Journal of Child Psychology and Psychiatry > 62-2 (February 2021) . - p.114-139[article] Research Review: Pediatric anxiety disorders - what have we learnt in the last 10 years? [Texte imprimé et/ou numérique] / Jeffrey R. STRAWN, Auteur ; Lu LU, Auteur ; Tara S. PERIS, Auteur ; Amir LEVINE, Auteur ; John T. WALKUP, Auteur . - 2021 . - p.114-139.
Langues : Anglais (eng)
in Journal of Child Psychology and Psychiatry > 62-2 (February 2021) . - p.114-139
Mots-clés : Generalized anxiety disorder Sri) fMRI pharmacogenomics selective serotonin reuptake inhibitor (SSRI separation anxiety disorder Index. décimale : PER Périodiques Résumé : BACKGROUND: Anxiety disorders first emerge during the critical developmental periods of childhood and adolescence. This review synthesizes recent findings on the prevalence, risk factors, and course of the anxiety disorders; and their neurobiology and treatment. METHODS: For this review, searches were conducted using PubMed, PsycINFO, and clinicaltrials.gov. Findings related to the epidemiology, neurobiology, risk factors, and treatment of pediatric anxiety disorders were then summarized. FINDINGS: Anxiety disorders are high prevalence, and early-onset conditions associated with multiple risk factors including early inhibited temperament, environment stress, and structural and functional abnormalities in the prefrontal-amygdala circuitry as well as the default mode and salience networks. The anxiety disorders are effectively treated with cognitive behavioral therapy (CBT), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine reuptake inhibitors (SNRIs). CONCLUSIONS: Anxiety disorders are high prevalence, early-onset conditions associated with a distinct neurobiological fingerprint, and are consistently responsive to treatment. Questions remain regarding who is at risk of developing anxiety disorders as well as the way in which neurobiology predicts treatment response. En ligne : http://dx.doi.org/10.1111/jcpp.13262 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=440